Acurx Pharmaceuticals, Inc. (ACXP) Stock

Acurx Pharmaceuticals, Inc. (ACXP) is a Healthcare stock trading at $1.48 (as of 2026-08-21), with a market capitalization of $6.36M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing antibiotics for bacterial infections. Its pipeline includes ibezapolstat for Clostridium difficile and ACX-375C for gram-positive bacteria, including MRSA, VRE, and penicillin-resistant Streptococcus pneumoniae.

Understand Acurx Pharmaceuticals, Inc.: how it makes money

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing antibiotics for bacterial infections, including ibezapolstat (targets polymerase IIIC, completed Phase II for Clostridium difficile infections) and ACX-375C (an oral and parenteral candidate targeting gram-positive bacteria).

Because the company is clinical stage and its described pipeline has not been commercialized here, its profit model is structurally tied to progressing ibezapolstat and ACX-375C through clinical development to reach approval and eventual commercialization.

Business quality (Weak): Pipeline progress matters most, but with no reportable segment or operating KPI provided and the latest results showing 0.0B revenue, the near-term business is still dominated by clinical development execution and outcomes.

Bull case

  • Lead and pipeline candidates with defined clinical and target biology: Ibezapolstat completed Phase II for Clostridium difficile infections and ACX-375C is being developed for gram-positive targets including MRSA, VRE, and penicillin-resistant Streptococcus pneumoniae.

Bear case

  • No disclosed commercial revenue in the provided latest period: For the latest reported period (2026-03-31), revenue is shown as 0.0B, implying results depend heavily on non-commercial activities until candidates reach commercialization.
  • Clinical development uncertainty can delay or derail value creation: The company is described as clinical stage, so future outcomes depend on whether ongoing development leads to successful clinical results and regulatory approval for its candidates.
  • Large operating losses reflected in the latest period: The latest reported operating margin is -4901.7%, indicating substantial operating losses during the period shown.
Valuation — source: SEC EDGAR (first-party)
Price$1.48
Market Cap$6.36M
Price / Book0.78
Price / Sales40.01
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$125445.00
Net Margin-6350.6%
Revenue Growth (YoY)523.4%
EPS Growth (YoY)511.5%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJANE STREET GROUP, LLC ($202722.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid Luci
Employees4
CountryUS
IPO Date2021-06-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Bolt Biotherapeutics, Inc. (BOLT)
  • Enveric Biosciences, Inc. (ENVB)
  • Dermata Therapeutics, Inc. (DRMA)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • Pulmatrix, Inc. (PULM)
  • Lakewood-Amedex Biotherapeutics Inc. (LABT)
  • Aptevo Therapeutics Inc. (APVO)
ACXP earnings history · ACXP institutional & insider holders · ACXP KPIs & operating metrics · ACXP financials · ACXP investor presentations & press releases · ACXP SEC filings · ACXP peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.